Indian Biotechs Seek To Outsource Drug Marketing To MNCs
This article was originally published in PharmAsia News
In somewhat of a trend reversal, some Indian biotechs are outsourcing their own drug projects as the drug-making business tightens. Avesthagen and Biocon have their own pipeline of drugs in development, but are discussing possible partnerships with multinational drug makers. Avesthagen has a nutritional molecule in clinical trials and seeks a MNC willing to market the drug while Avesthagen focuses on four other molecules in the pre-clinical stage. Biocon is in a similar situation with an insulin molecule just entering Phase III trials. (Click here for more
You may also be interested in...
A recent segment of CBS News “60 Minutes” discussing potential health benefits from probiotics was highly criticized by groups including the Consumer Healthcare Products Association, the Council for Responsible Nutrition, the Natural Products Association and the International Probiotics Association.
After a 12-month period that has seen Stada make significant investments in generics, biosimilars and consumer healthcare, CEO Peter Goldschmidt tells Generics Bulletin that the firm does not intend to stop there, as it pursues both organic and inorganic growth opportunities.
Samsung Bioepis is the latest company to stare down a lawsuit from Genentech over Avastin patents in the US. The Korean firm is aiming to be amongst the early biosimilar movers, after the market formed a year ago.